Kaleido Biosciences IncGrey Market:KLDO
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KLDO |
|---|---|---|
| 09:35 ET | 1303 | 0.0001 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kaleido Biosciences Inc | 4.3K | 0.0x | --- |
Mymetics Corp | 150.0 | 0.0x | --- |
Baudax Bio Inc | 40.0 | 0.0x | --- |
Quick-Med Technologies Inc | 40.0 | 0.0x | --- |
Affymax Inc | 30.0K | 0.0x | --- |
Statera Biopharma Inc | 7.1K | 0.0x | --- |
Company Information
Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on microbiome organs to treat disease and improve human health. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. It is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development for the prevention of infections caused by multi-drug resistant (MDR) bacteria. The nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.
Contact Information
- Headquarters
- 18 Crosby DriveBEDFORD, MA, United States 01730
- Phone
- 617-674-9000
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Theo Melas-Kyriazi
- Independent Director
- Bonnie Bassler
- Independent Director
- Jean Mixer
- Independent Director
- Anne Prener
- Independent Director
- Anthony Quinn
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.3K |
|---|---|
Revenue (TTM) | $1.1M |
Shares Outstanding | 42.6M |
Kaleido Biosciences Inc does not pay a dividend. | |
Beta | --- |
EPS | $-2.16 |
Book Value | $0.25 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -7,940.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
